FDA approves new use of GlaxoSmithKline's asthma treatment Nucala (mepolizumab)
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, GlaxoSmithKline (GSK) announced that the UsThe FDA(http://approved a new use of its asthma treatment, Nucala.,As an IL-5 inhibitor, Nucala is a class of monoclonal antibody therapy for "first-in-class"By inhibiting IL-5, it is expected to reduce the growth of eosinophils and relieve severe asthma symptomsIn 2015, it was approved by the U.SFDA for treatment of severe asthmaTo improve the patient's drug experience, GSK researchers have developed a new way to use Nucala in a self-injectable syringe that allows patients or health care providers to be injected every four weeks to control the conditionin two publicly labeled, single-arm, 3a clinicaltrial(http://, based on real-world dataanalysis(http://, the researchers found that after training, patients can successfully learn how to inject themselves and treat themanother clinical trial has shown that the new use is similar in pharmacokinetics and pharmacodynamics to previously approved dry powder preparations
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
